Marc Güell wins the Spanish National Research Award for Young People 2022

Dr Marc Güell has received the Ángela Ruiz Robles 2022 National Research Award for Young People, in the field of technology transfer, awarded by the Ministry of Science and Innovation of Spain. He was recognised for his contributions in harnessing synthetic biology to generate new basic principles of molecular biology for the design of biological […]

Integra Therapeutics and Caszyme receive €1-million Eurostars grant

Integra Therapeutics has been awarded €1-million grant from Eurostars, the largest funding programme of the European Commission that supports innovative SMEs in developing collaborative transnational projects geared towards the market. The company applied for the call as part of a consortium with Caszyme, a Lithuanian company that specialises in CRISPR technology and molecular tools development […]

Integra Therapeutics receives Catalan Society of Biology Award 2022

Integra Therapeutics has received the Catalan Society of Biology (SCB) Award for best innovative start-up of 2022 for developing the next-generation of gene writing tools for therapeutic purposes in the field of life sciences. The SCB Board of Directors recognised Integra Therapeutics’ innovative technology, the benefit to society and the team‘s ability to bring the […]

Marc Güell, new member of Young Academy of Spain

Dr Marc Güell, co-founder of Integra Therapeutics and principal investigator of the Translational Synthetic Biology Laboratory at Pompeu Fabra University (UPF), has been made a member of the Young Academy of Spain (AJE) after a selection process with 87 candidates. He will belong to the AJE for five years. This makes Dr Güell an Academic […]

Avencia Sánchez-Mejías receives Women and Leadership Award

Dr Avencia Sánchez-Mejías, co-founder and CEO of Integra Therapeutics, won the first edition of the Women and Leadership Award promoted by Deusto Business School, Cinco Días and Banco Santander to boost and raise awareness of the talent of female executives at companies and in entrepreneurship. The ceremony was held on 2 June at the business […]

Integra Therapeutics appoints Mark Bonyhadi as new independent director

Integra Therapeutics announced today that Dr Mark Bonyhadi has been appointed to its Board of Directors as an independent director. Dr Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to […]

Integra Therapeutics at ‘CRISPR News Medicine’

CRISPR News Medicine publishes an article entitled Adaptation of jumping gene boosts CRISPR-Cas gene-writing technology to new heights about new FiCAT platform developed by Integra Therapeutics. By Henri van de Vrugt